Reversible Acetylation Regulates Salt-Inducible Kinase (SIK2) and Its Function in Autophagy*

Fu-Chia Yang1,2,3,11, Bertrand Chin-Ming Tan4,11, Wei-Hao Chen1,11, Ya-Huei Lin1, Jing-Yi Huang1, Hsin-Yun Chang1, Hui-Yu Sun1, Pang-Hung Hsu5, Gunn-Guang Liou6, James Shen7, Ching-Jin Chang2,8, Chau-Chung Han9, Ming-Daw Tsai5,8, and Sheng-Chung Lee1,8,10

From the 1Institute of Molecular Medicine, 2Institute of Biochemical Sciences, and 10Institute of Clinical Medicine, National Taiwan University, Taipei 100, Taiwan

4Department of Biomedical Sciences, Chang Gung University, Tao-Yuan 33302, Taiwan

3Chemical Biology and Molecular Biophysics Program, Taiwan International Graduate Program,

5Genomics Research Center, 7Institute of Molecular Biology, 8Institute of Biological Chemistry, and

9Institute of Molecular and Atomic Sciences, Academia Sinica, Taipei 11529, Taiwan

6Division of Molecular and Genomic Medicine, National Health Research Institute, Miaoli 35053, Taiwan

11These authors contributed equally to this work

*Running title: Acetylation regulates SIK2 in autophagy

To whom correspondence should be addressed: Sheng-Chung Lee, Institute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei 10051, Taiwan. Tel: 886-2-2356-2982; Fax: 886-2-2321-0977; E-mail: slee@ntu.edu.tw.

Keywords: SIK2; acetylation; autophagy; p300/CBP; HDAC6; TDP-43

Background: SIK2 is an AMPK-family kinase that mediates hormonal and nutrient signaling but has no known link to cellular stress response.

Results: p300/CBP and HDAC6 reciprocally regulate Lys53 acetylation of SIK2, consequently impacting its activity and function in autophagosome maturation.

Conclusion: SIK2 kinase activity, via acetylation-based regulatory switch, contributes to autophagy progression.

Significance: SIK2 may be linked to neurodegenerative or protein aggregate disorders.

SUMMARY

Salt-inducible kinase 2 (SIK2) is a serine/threonine protein kinase belonging to the AMP-activated protein kinase (AMPK) family. SIK2 has been shown to function in the insulin-signaling pathway during adipocyte differentiation and to modulate CREB-mediated gene expression in response to...
hormones and nutrients. However, molecular mechanism underlying the regulation of SIK2 kinase activity remains largely elusive. Here we report a dynamic, post-translational regulation of its kinase activity that is coordinated by an acetylation-deacetylation switch – p300/CBP-mediated Lys53-acetylation inhibits SIK2 kinase activity, while HDAC6-mediated deacetylation restores the activity. Interestingly, overexpression of acetylation-mimetic mutant of SIK2 (SIK2-K53Q), but not the non-acetylatable K53R variant, resulted in accumulation of autophagosomes. Further consistent with a role in autophagy, knockdown of SIK2 abrogated autophagosome and lysosome fusion. Consequently, SIK2 and its kinase activity are indispensable for the removal of TDP-43Δ inclusion bodies. Our findings uncover SIK2 as a critical determinant in autophagy progression and further suggest a mechanism in which the interplay among kinase and deacetylase activities contributes to cellular protein pool homeostasis.

Salt-inducible kinase 2 (SIK2) is a member of the AMP-activated protein kinase (AMPK) family, constituents of which are regarded as important mediators of energy and stress signaling. The kinase activity of SIK2 has been shown to regulate a number of signaling pathways and associated gene expression in response to hormones and nutrients. Particularly, its link to the insulin-signaling pathway was evidenced by phosphorylation of IRS-1 during adipocyte differentiation (1), and phosphorylation of coactivator transducer of regulated CREB activity (TORC2) during insulin-modulated gluconeogenesis (2,3). Bricambert et al also showed that SIK2 inhibits ChREBP-mediated hepatic lipogenesis and steatosis in mice through inhibitory phosphorylation of p300 HAT on Ser89 (4). Furthermore, SIK2 is known to regulate the initiation of mitosis through phosphorylating the centrosome linker protein, C-Nap1 (5). An intimate link between SIK2 and the CREB coactivator TORC1/2 has also been established, particularly in the contexts of melanogenesis (6,7), cerebral ischemia-associated neuronal survival (8), and corticotropin-releasing hormone transcription (9). However, as an AMPK family kinase, its possible functional link to cellular stress response has not been reported and requires further clarification.

In contrast to the activation of AMPK, in which the causal role of energy disturbance is well established, the physiological conditions that underlie the activation of SIK2 remain to be defined. Phosphorylation of SIK2 on Thr175 is the hallmark of its kinase activation. While LKB1 is known to activate 13 kinases of the AMPK family (10), low level of SIK2-Thr175 phosphorylation still persisted in the LKB1-null HeLa cells, thus implying additional regulatory mechanisms. Another potential key determinant of the post-translational regulation of SIK2 kinase lies in protein stability and protein-protein interaction. Interestingly, CaMK1-mediated phosphorylation on the Thr484 residue was previously shown to negatively regulate SIK2 protein level (8), while PKA modulates the interaction between SIK2 and 14-3-3 by Ser358 phosphorylation (11). However,
issues regarding other modes of modifications and regulation for this multi-functional kinase are currently unresolved.

In this report, we found a hitherto unrecognized requirement of SIK2 activity for autophagosome maturation. Importantly, our work also revealed a novel post-translational regulation of its kinase activity, which is coordinated by p300/CBP and HDAC6. Collectively, these results extended the known cellular roles of SIK2 to critical functions in autophagy, and further highlight a mechanism by which the interplay among kinase and acetylase/deacetylase activities contributes to cellular protein pool homeostasis.

EXPERIMENTAL PROCEDURES

DNA constructs and mutagenesis – The pBluescript II vector encoding SIK2 sequence (KIAA0781) was from HUGE, Japan. The DNA fragment encoding SIK2 was excised using SalI and XhoI sites in the pBluescript-SIK2 vector and sub-cloned into pCMV-FLAG mammalian expression vector (Stratagene, La Jolla, CA, USA). SIK2-K49M, SIK2-K53Q and SIK2-K53R were generated with the site-directed mutagenesis kit (Stratagene) according to manufacturer’s instructions. The pCMV-FLAG-SIK2 plasmid was used as template. The following primers were synthesized for creating the mutants: SIK2-KD (K49M):
5’-GGTGGCAATAATGATAATCGATAAG-3’; SIK2-K53R:
5’-GGCAATAAAAATAATCGATAAGGTCTCA
GCTGGATC-3’; SIK2-K53Q:
5’-GGCAATAAAAATAATCGATAGTCTCAG
TCTCAGGTGC-3’. The mutations were then confirmed by DNA sequencing. shRNAs against human SIK2 was generated by using pSuper RNAi system (Oligoengine, Seattle, WA, USA), with the target sequence for human SIK2 (NM_015191.1)
5’-GCAGTTGTGTATGAACAA-3’. siRNAs targeting SIK1 and SIK2 were acquired from Dharmacon (Chicago, IL, USA). All plasmids were verified by sequencing.

Antibodies and recombinant proteins – Anti-ubiquitin monoclonal antibody was from Millipore (Bedford, MA, USA), and anti-GFP monoclonal antibody was originated from Clontech (Palo Alto, CA, USA). Monoclonal antibodies to SIK2 (clone 15G10) and α-tubulin (clone 10D8), as well as rabbit-derived anti-FLAG-tag, anti-β-actin, and anti-γ-tubulin antibodies were generated in the lab and affinity purified according to standard protocol. For SIK2, rabbit anti-phospho-Thr175 antibody were generated by KLH-conjugated phospho-peptide, ELLAT*WSGSPPY. Recombinant HDAC1-8 proteins were isolated by immunoprecipitation of cell-free extracts from HEK293T cells transfected with FLAG-tagged recombinant expression plasmids.

Cell culture and transfection – HEK293T cells were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum and penicillin/streptomycin (100 units/ml) at 37°C in a 5% CO₂ humidified atmosphere. Calcium phosphate-mediated transfection of HEK293T cells was performed according to a standard protocol.

Immunoprecipitation and western blot analysis – Immunoprecipitation was performed as
previously described (12). Cells expressing recombinant FLAG-SIK2 were harvested and rinsed with PBS. Lysis buffer containing 20 mM Tris-HCl, pH 7.4, 0.15 M NaCl, 0.1% Triton X-100, 1 mM dithiothreitol (DTT), and protease inhibitors was used to prepare cell lysate. Cell lysates were immunoprecipitated with M2-agarose beads (Sigma-Aldrich) for 1 hr at 4°C. The agarose beads bound with FLAG-SIK2 were then washed 3 times with lysis buffer and subjected to PAGE. Western blot analysis was performed using the indicated antibodies and subsequently visualized using ECL chemiluminescence (PerkinElmer, Waltham, MA, USA) and X-ray films (Eastman Kodak Co., Rochester, NY, USA). Band signals were scanned before being quantified by the software Image gauge (Fujifilm, Tokyo, Japan).

**In-gel tryptic digestion and mass spectrometry** – In-gel tryptic digestion was performed with the previously described procedure (13). The peptides resuspended in 0.1% formic acid were analyzed using a quadrupole ion trap mass spectrometer (Esquire 3000 plus, Bruker-Daltonics, Leipzig, Germany) interfaced with a high-pressure liquid chromatograph system (UltiMate, LC Packings, San Francisco, CA, USA). A 150 × 0.5 mm C18 column (ZorbaxSB, Agilent Technologies, Palo Alto, CA, USA), and mobile phases consisting of 0.1% formic acid in water and of 0.1% formic acid in acetonitrile were used. An acetonitrile gradient from 15% to 60% in 60 minutes was performed to elute peptides from the column. The acquired mass spectra were then analyzed. Phosphorylation identification was also performed with LTQ-FT (Linear quadrupole ion trap-Fourier transform ion cyclotron resonance) mass spectrometer (Thermo Fisher Scientific, Inc., Waltham, MA, USA), an Agilent 1100 Series binary HPLC pump (Agilent Technologies), and a Famos autosampler (LC Packings).

**In vitro kinase assay** – The FLAG-SIK2 immune-complexes were washed with lysis buffer three times and once with kinase buffer (20 mM Tris-HCl pH 7.4, 10 mM MgCl2, 50 mM NaCl, 1 mM DTT, and 0.5 mM NaF). Kinase reaction was performed by adding kinase buffer plus 50 µM ATP and 5 µCi [γ-32P]ATP into the precipitates, followed by incubation at 30°C for 15 minutes. Reaction was stopped by adding sample buffer, followed by SDS-PAGE and autoradiography.

**In vitro deacetylation assay** – For in vitro deacetylation assay, HDAC6 immunoprecipitated with M2 beads were washed with lysis buffer three times and twice with deacetylation buffer (10 mM Tris-HCl pH 8.0 and 150 mM NaCl). The immune-complexes were subsequently incubated with purified SIK2 in 10 µl of deacetylation buffer for 2 hrs at 37°C. Reaction was terminated with SDS sample buffer, and subjected to SDS-PAGE and immunoblotting.

**[γ-35S]ATP binding assay** – Binding of [γ-35S]ATP by wild-type and mutant proteins was performed in 10-µl binding buffer containing 25 mM HEPES (pH 8.1), 100 mM NaCl, 5 mM MgCl2, 1 mM DTT, 11% glycerol and 9.6 µM [γ-35S]ATP (65 Ci/mmol, 12.5 mCi/ml) at 37°C for 20 min. [γ-35S]ATP was crosslinked to proteins by a 5-min UV irradiation on ice in a UV crosslinker. The reactions were then resolved by SDS-PAGE and visualized by autoradiography.
Immunofluorescence staining and confocal microscopy – Cells grown on coverslips were washed with PBS and fixed with 4% formaldehyde in PBS. The cells were permeabilized with 0.5% Triton X-100 in PBS and blocked by 1% BSA prior to being probed with the indicated antibodies. Alexa 488-conjugated goat anti-rabbit IgG, Alexa 594-conjugated goat anti-rabbit IgG, and Alexa 594-conjugated goat anti-mouse IgG (Invitrogen) were used as secondary antibodies. The cells were counter-stained with Hoechst to visualize DNA. For the cells expressing GFP-SIK2 and red-fluorescent ER marker, they were stained with DAPI immediately after the fixation step. Images were acquired using an inverted confocal microscopy (LSM-510, Zeiss, Thornwood, NY, USA) installed with a 63×/NA 1.4 oil immersion objective lens. For quantification, five to ten fields were randomly selected from each sample for analysis.

Electron microscopy – The sample preparation procedure followed a common standard protocol with modification. Briefly, after fixation, the cells were neutralized with 0.1 M ammonium chloride and embedded with LR-Gold reagent (London Resin Co., Reading, Berkshire, UK). The ultrathin sections of embedded samples were stained with uranyl acetate and lead citrate. Samples were examined using either a Jeol JEM 2100F (JEOL Ltd., Tokyo, Japan) or an FEI Tecnai T12 electron microscope (FEI Co., Eindhoven, Netherlands).

Preparation of soluble/insoluble fractions and slot blot analysis – Cells were harvested and extracted with whole cell extraction buffer (0.15 M NaCl, 20 mM Tris-HCl pH 7.6, 0.1% Triton X-100) containing protease inhibitors and phosphatase inhibitors (1 mM PMSF, 1 µg/ml leupeptin, 1 µg/ml pepstain A, 1 mM DTT, 5 µM NaF, 1 mM Na3VO3) and 1 mM sodium butyrate. Lysates were passed through 25 G-needle 10 times using syringe. Soluble and insoluble fractions were separated by centrifugations at 12,000 × g for 20 mins. Insoluble fraction was resuspended in 6 M urea and sonicated for 15 seconds. Protein concentrations were determined by Bio-Rad Protein Assay (Bio-Rad, Hercules, CA, USA). Ten µg of soluble and insoluble fractions were mixed with SDS sample buffer and separated by SDS-PAGE for analysis. For slot blot analysis, supernatant of urea-dissolved insoluble fraction was collected upon centrifugation and filtered through 0.22 µm nitrocellulose membrane with Minifold II Slot-Blot System (Schleicher and Schuell, Keene, NH, USA).

Statistical analysis – The data were analyzed with student’s t-test. Data were mean ± SD. P values < 0.05 were considered significant.

RESULTS

Lys53 is a major acetylation site of SIK2 that is catalyzed by p300 and CBP. To deduce the regulatory mechanisms of SIK2 kinase activity, we first aimed to characterize post-translational modifications on SIK2 through mass spectrometric analysis of recombinant SIK2-WT protein recovered from HEK293T cells. The MS/MS spectra revealed that SIK2 undergoes acetylation on Lys53 (Fig. 1A) as well as phosphorylation on Ser358 and Ser587 (Supplemental Fig. S1). As the
phosphorylation sites were previously reported (11,14), we thus focused on further characterizing the acetylation modification. Next, to pinpoint the acetyltransferase responsible for this acetylation, we co-expressed p300, CBP, or Tat-interactive protein 60 (Tip60) with SIK2 and examined the acetylation level of SIK2. We discovered that SIK2 acetylation was enhanced by ectopic expression of p300 or CBP but remained unaltered in the presence of Tip60 (Fig. 1B), indicating their possible regulatory roles. To verify whether the p300/CBP-mediated acetylation is specific to Lys53 residue of SIK2, we co-expressed SIK2-WT or the non-acetylatable mutant (K53R) with p300. Immunoblotting analysis showed that the acetylation level of SIK2-K53R mutant protein was abolished (Fig. 1C), demonstrating that Lys53 is a predominant acetylation site on SIK2 targeted by p300. Similar results were obtained when the experiment was performed with CBP (data not shown).

Lys53-acetylation inhibits the ATP-binding ability and kinase activity of SIK2. Since Lys53 of SIK2 is a major acetylation site and located 4 residues C-terminal to the known ATP-binding residue Lys49, we thus hypothesized that acetylation on this residue might affect SIK2’s ATP-binding ability and kinase activity due to charge alteration. To address this issue, we performed in vitro ATP-binding assay on SIK2-KD (a K49M, kinase-dead mutant) and the acetylation-mimetic SIK2-K53Q variant. The K53Q mutant clearly exhibited a deficiency in ATP binding comparable to that of the KD mutant (Fig. 2A), implying that a neutralization of charge by acetylation affects ATP binding. Next, we examined kinase activation by monitoring the phosphorylation of Thr175 in the activation loop on both wild type and mutant SIK2s (Fig. 2B). The immunoblotting results first indicated that Thr175 phosphorylation of SIK2-KD was abolished, suggesting that this phosphorylation is mediated by autophosphorylation. Further, Thr175 phosphorylation of the K53Q variant was reduced while the K53R form exhibited comparable phosphorylation as SIK2-WT, indicating that the kinase activity is indeed impaired by Lys53 acetylation. As a means to further assess the kinase activity of the acetylation mutants, immunoprecipitated recombinant SIK2 was subjected to in vitro kinase assay with GST-Syntide2 as the substrate. As shown in Figure 2C, Syntide-2 was phosphorylated by the SIK2-K53Q mutant to a significantly lesser extent than by SIK2-WT or SIK2-K53R, providing further evidence that Lys53 acetylation suppresses SIK2 kinase activity. Consistent with the above observation (Fig. 2B), autophosphorylation of SIK2 correlated with its activity toward Syntide-2, as indicated by the extent of phosphorylation. Taken together, these results indicate that SIK2 is inactivated by p300/CBP-mediated acetylation of Lys53 in the vicinity of the ATP-binding pocket.

HDAC6 activates SIK2 by reversing acetylation at Lys53. In an attempt to search for the enzyme that deacetylates SIK2 on Lys53, a peptide containing an acetylated Lys53 (KIIDK*SQLDAC) was used for in vitro deacetylation assay in conjunction with purified recombinant HDAC1, 2, 3, 4, 5, 6, and 8 proteins. Upon performing LC-MS/MS analyses, we found that only HDAC6 could deacetylate the synthetic
acetyl-peptide (Fig. 3A). Furthermore, the acetylation level of SIK2 was significantly reduced when HDAC6 was overexpressed in the cells, indicating that HDAC6 deacetylates SIK2 in vivo (Fig. 3B). Such decline in SIK2 acetylation was not observed when cells expressed a catalytically inactive HDAC6 mutant or HDAC3 (Fig. 3B, lanes 5 and 6), further supporting a specific requirement for the deacetylase activity of HDAC6. To further clarify whether HDAC6 counterbalances p300-mediated SIK2 acetylation, we performed an in vitro deacetylation assay of acetylated-SIK2. Acetylated-SIK2 was first immunoprecipitated from cells co-expressing p300 and SIK2 in the presence of trichostatin A (TSA). The in vitro deacetylation reaction was then performed with recombinant HDAC6, HDAC3, or SIRT1 in the presence or absence of inhibitors. As shown in Figure 3C, SIK2 acetylation level decreased when incubated with HDAC6 (lane 5), whereas it remained unchanged in the presence of catalytically inactivated HDAC6 mutant (HDAC6-CD) or the HDAC inhibitor TSA (lanes 6-7). Further, HDAC3 or SIRT1 did not affect the acetylation level of SIK2 (Fig. 3C, lanes 3-4 and 8-9). Similar data were obtained when CBP was expressed (data not shown). Collectively, these data suggest that p300/CBP and HDAC6 specifically and reciprocally regulate the acetylation level of SIK2/Lys53.

For further confirmation of the role of acetylation/deacetylation in the regulation of SIK2 activity, we probed the phosphorylation level of SIK2/Thr175 in the context of CBP and HDAC6 over-expression. The results showed that Thr175 phosphorylation was inhibited by CBP, while overexpression of HDAC6 restored the CBP-mediated inhibition of Thr175 phosphorylation (Fig. 3D). These findings thus imply a reversible SIK2 activity regulatory switch that hinge on Lys53 acetylation/deacetylation.

Acetylation elicits SIK2 sequestration to autophagosomes. Having demonstrated the kinase inhibitory effect of Lys53-acetylation on SIK2, we then sought to assess whether this modification alters cellular attributes of SIK2 such as subcellular localization. To this end, immunofluorescence staining analysis of SIK2-WT, SIK2-KD, or the acetylation site mutants was performed. In contrast to the wild-type SIK2 and K53R mutant, which exhibited diffused patterns of cytoplasmic distribution, the kinase-deficient mutants, KD and K53Q, were found sequestered in autophagosome structures characterized by LC3 (Fig. 4A). This observation suggests that SIK2’s subcellular localization relies on its Lys53 acetylation as well as kinase activity. To further corroborate the role of acetylation on the spatial co-localization of SIK2 with autophagosomes, we performed additional experiments on cells co-transfected with CBP and SIK2-WT or SIK2-K53R. Confocal microscopy analysis illustrated that co-expression of CBP indeed promoted accumulation of SIK2 in aggresomes, whereas the non-acetylatable K53R remained in cytosol (Fig. 4B), supporting the notion that acetylation of SIK2 underlies such unique distribution.

Notably, in response to MG132-mediated proteasome inhibition, even the wild-type form of SIK2 was sequestered to autophagosomes (Fig. 4A, rightmost panel). The endogenous SIK2 protein...
also exhibited this spatial overlap with autophagosome upon proteasome blockade (Fig. 4C). We further confirmed this observation by analyzing protein expression in the soluble and insoluble fractions of the MG132-treated cell extracts (Fig. 4D). In this assay, no contamination of insoluble fraction with soluble constituents was evidenced by the presence of $\gamma$-tubulin and absence of $\alpha$-tubulin. In line with the regulated subcellular distribution, the protein level of endogenous SIK2, similarly to ubiquitinated-protein levels, was elevated in the insoluble fraction after MG132 treatment (Fig. 4D, compare lanes 2 and 4). Additionally, congruent with the above observations that linked acetylation state of SIK2 to its stress-associated distribution, acetylation level of SIK2 was elevated after MG132 treatment (Fig. 4E). Together, these findings therefore suggest that stalled protein turnover may trigger a dynamic, acetylation-dependent distribution of SIK2, and further signify its link to aggregated protein removal.

**SIK2 is indispensible for the processing of autophagosomes.** Abnormal accumulation of autophagosomes thus implies that the kinase activity of SIK2 may be required for facilitating the clearance of aggregated proteins. To next explore this possibility, we utilized a pH-sensitive mCherry-GFP-LC3, whose GFP ceases to fluoresce once fused with lysosome (15), to examine autophagosome-lysosome fusion efficiency in SIK2-knockdown HEK293T cells. The immunofluorescence staining data subsequently revealed that knockdown of SIK2, but not SIK1, led to persisted GFP signals, thus indicating a disrupted autophagosome-lysosome fusion (Fig. 5A). Correspondingly, fine structure analysis using transmission electron microscopy revealed marked accumulation of autophagosome structures in the absence of SIK2 (Fig. 5B), suggesting a positive role of SIK2 in the processing of autophagosomes.

**SIK2 activity is required for the clearance of TDP-43$\Delta$ inclusion bodies.** Owning to the possible role of SIK2 in mediating removal of aggregated proteins, we next set out to address whether SIK2 is associated with aggregated proteins in inclusion bodies. To this end, we transfected a 25-kDa truncated form of TDP-43, a pathological signature of neurodegeneration (16-18), into HEK293T cells and examined the subcellular localization of relevant proteins. Immunofluorescence staining analysis demonstrated partial co-localization of endogenous SIK2 with the ubiquitin-positive TDP-43$\Delta$ inclusion bodies in the perinuclear region (Fig. 6A). Interestingly, SIK2-KD completely coincided with TDP-43$\Delta$ inclusion bodies as compared to the limited co-localization displayed by SIK2-WT (Fig. 6B). Together, these results suggest that SIK2 could be sequestrated to TDP-43$\Delta$-associated inclusion bodies, and may further imply a functional relevance.

To next investigate whether SIK2 participates in the removal of aggregated proteins, slot blot was performed to analyze the level of TDP-43$\Delta$ in insoluble fraction of SIK2-depleted cells. As illustrated in Figure 7A, TDP-43$\Delta$ accumulated in insoluble fraction when SIK2 was downregulated. Similarly, overexpression of SIK2-WT and SIK2-K53R resulted in lower levels
of TDP-43Δ in the insoluble fraction as compared to the vector control, while SIK2-KD and SIK2-K53Q led to TDP-43Δ accumulation in the insoluble fraction (Fig. 7B). Next, we quantified the number of inclusion bodies-containing cells in the presence of SIK2-WT/KD or SIK2-targeting shRNA, and subsequently found increased occurrence of such aberrant cells upon SIK2-KD overexpression (Fig. 7C, left) or SIK2 ablation by RNAi (Fig. 7C, right). These results are consistent with the above observations of autophagosome accumulation (Fig. 4A and Fig. 5B), and recapitulate the notion that the kinase activity of SIK2 represents a critical determinant for autophagosome maturation and aggresome removal.

DISCUSSION

In this paper, we uncovered a two-component regulatory switch for the SIK2 kinase activity and function — kinase autoactivation and the acetylation/deacetylation-mediated inactivation/activation. p300/CBP-mediated Lys53-acetylation inhibited SIK2 kinase activity, while HDAC6-mediated deacetylation restored the activity. Importantly, alterations in the ATP-binding pocket, exhibited by the kinase-dead (K49M) and acetylation-mimetic (K53Q) variants, were shown to impede the phosphorylation of Thr175 (Fig. 2B). Therefore, as a single-polypeptide member of the AMPK family, autophosphorylation of SIK2 on activation loop (Thr175) may represent a distinct feature of its kinase activation. Intriguingly, SIK2 was previously shown to target p300 HAT through inhibitory phosphorylation on Ser89 (4). Our present study thus raises the possibility of a feedback mechanism that cross-regulates these two enzymatic activities, which may have significant functional implications in processes such as gene expression and autophagy.

In addition to the inhibition of SIK2 activity, acetylation also led to sequestration of SIK2 in autophagosomes. Remarkably, proteasome inhibition by MG132 resulted in sequestration of SIK2 to autophagosomes as well as elevation of its acetylation level (Fig. 4). Interestingly, we also found that the stability of SIK2 is dependent on the heat-shock protein HSP90 and negatively regulated by proteasome-mediated turnover (Y. H. Lin, unpublished data). These observations prompted us to assume that SIK2 might play a regulatory role in autophagy induced by proteasome inhibition. Supporting this assumption, we further demonstrated that SIK2 is indispensible for autophagosome processing (Fig. 5). Unexpectedly, our present results have shown some similarities as well as discrepancies in the phenotypes between knockdown of SIK2 and overexpression of SIK2-KD or SIK2-K53Q – while knockdown of SIK2 resulted in compromised autophagosome maturation (Fig. 5), overexpression of SIK2-KD or SIK2-K53Q triggered a more severe extent of aggresome accumulation than SIK2 knockdown (Fig. 4A). This unique phenotype may be attributed to a forced sequestering of aggregated proteins to the aggresomes by the overexpressed SIK2-K53Q or SIK2-KD. In support of this premise, we have observed that highly elevated levels of polyubiquitinated proteins were
immunoprecipitated with overexpressed SIK2-KD as compared to SIK2-WT (Y. H. Lin and C. T. Chuang, unpublished data).

Furthermore, there is emerging evidence suggesting the critical role of acetylation in autophagy regulation (19-21). Both p300 and HDAC6, the enzymes controlling SIK2 acetylation, were previously reported as key regulators of autophagy. p300 modulates autophagy through augmentation of Atg5, Atg7, Atg8, and Atg12 acetylation (19), and HDAC6 is required for the formation and maturation of autophagy (22,23). Therefore, it seems very likely that the function of SIK2 in autophagy is regulated through reversible modification controlled by p300 and HDAC6. Our results are consistent with the scenario that, upon inactivation of SIK2 by p300/CBP-mediated Lys53-acetylation and its subsequent sequestration to autophagosomes, SIK2 may undergo deacetylation at Lys53 by HDAC6 and regain its kinase activity required for the subsequent maturation of autophagosome (Fig. 8). Thus, the present findings provide a physiological explanation for how SIK2 is functioning in autophagy in a kinase activity-dependent manner.

The physiological as well pathophysiological significance of autophagy is evidenced by its link to many diseases including cancer and neurodegeneration (24,25). Autophagy is intricately linked to cancer – it may serve to inhibit continuous cell growth at early stage while promote transformed cells survival by recycling damaged organelles (24). In contrast, autophagy is thought to protect cells against neurodegenerative disorders (26,27). Notably, the anomalous autophagic structures in the SIK2 knockdown cells (Fig. 5B) were also observed in dystrophic neuritis of Alzheimer’s disease patients (28). More importantly, we demonstrated that the kinase activity of SIK2 is required for the clearance of TDP-43 truncated fragment aggregates, which are the hallmark of several neurodegenerative diseases, such as frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) (29-31). Given that SIK2 was recently found highly expressed in neurons (8), our observations of its involvement in autophagosome processing and TDP-43Δ inclusion bodies removal strongly imply a protective role of this kinase in neurons. Hence, the development of agonists for boosting SIK2 activity or inhibitors of SIK2 Lys53-acetylation, both of which presumably would facilitate autophagy, might be an effective pharmacological strategy in treating neurodegenerative or protein aggregate disorders.
REFERENCES

1. Horike, N., Takemori, H., Katoh, Y., Doi, J., Min, L., Asano, T., Sun, X. J., Yamamoto, H., Kasayama, S., Muraoka, M., Nonaka, Y., and Okamoto, M. (2003) J. Biol. Chem. 278, 18440-18447

2. Dentin, R., Liu, Y., Koo, S. H., Hedrick, S., Vargas, T., Heredia, J., Yates, J., 3rd, and Montminy, M. (2007) Nature 449, 366-369

3. Muraoka, M., Fukushima, A., Viengchareun, S., Lombes, M., Kishi, F., Miyauchi, A., Kanematsu, M., Doi, J., Kajimura, J., Nakai, R., Uebi, T., Okamoto, M., and Takemori, H. (2009) Am. J. Physiol. Endocrinol. Metab. 296, E1430-1439

4. Bricambert, J., Miranda, J., Benhamed, F., Girard, J., Postic, C., and Dentin, R. (2010) J. Clin. Invest. 120, 4316-4331

5. Ahmed, A. A., Lu, Z., Jennings, N. B., Etemadmoghadam, D., Capalbo, L., Jacamo, R. O., Barbosa-Morais, N., Le, X. F., Vivas-Mejia, P., Lopez-Berestein, G., Grandjean, G., Bartholomeusz, G., Liao, W., Andreiff, M., Bowtell, D., Glover, D. M., Sood, A. K., and Bast, R. C., Jr. (2010) Cancer Cell 18, 109-121

6. Horike, N., Kumagai, A., Shimono, Y., Onishi, T., Itoh, Y., Sasaki, T., Kitagawa, K., Hatano, O., Takagi, H., Susumu, T., Teraoka, H., Kusano, K., Nagaoka, Y., Kawahara, H., and Takemori, H. (2010) Pigment Cell Melanoma Res. 23, 809-819

7. Kumagai, A., Horike, N., Satoh, Y., Uebi, T., Sasaki, T., Itoh, Y., Hirata, Y., Uchio-Yamada, K., Kitagawa, K., Uesato, S., Kawahara, H., Takemori, H., and Nagaoka, Y. (2011) PLoS One 6, e26148

8. Sasaki, T., Takemori, H., Yagita, Y., Terasaki, Y., Uebi, T., Horike, N., Takagi, H., Susumu, T., Teraoka, H., Kusano, K., Hatano, O., Oyama, N., Sugiyama, Y., Sakoda, S., and Kitagawa, K. (2011) Neuron 69, 106-119

9. Liu, Y., Poon, V., Sanchez-Watts, G., Watts, A. G., Takemori, H., and Aguilera, G. (2012) Endocrinology 153, 223-233

10. Lizcano, J. M., Goransson, O., Toth, R., Deak, M., Morrice, N. A., Boudeau, J., Hawley, S. A., Udd, L., Makela, T. P., Hardie, D. G., and Alessi, D. R. (2004) EMBO J. 23, 833-843

11. Henriksson, E., Jones, H. A., Patel, K., Peggie, M., Morrice, N., Sakamoto, K., and Goransson, O. (2012) The Biochemical journal 444, 503-514

12. Huang, J. Y., Chen, W. H., Chang, Y. L., Wang, H. T., Chuang, W. T., and Lee, S. C. (2006) Nucleic Acids Res. 34, 2398-2407

13. Tsay, Y. G., Wang, Y. H., Chiu, C. M., Shen, B. J., and Lee, S. C. (2000) Anal. Biochem. 287, 55-64
Acetylation regulates SIK2 in autophagy

14. Screaton, R. A., Conkright, M. D., Katoh, Y., Best, J. L., Canettieri, G., Jeffries, S., Guzman, E., Niessen, S., Yates, J. R., 3rd, Takemori, H., Okamoto, M., and Montminy, M. (2004) Cell 119, 61-74

15. Pankiv, S., Clausen, T. H., Lamark, T., Brech, A., Bruun, J. A., Outzen, H., Overvatn, A., Bjorkoy, G., and Johansen, T. (2007) J. Biol. Chem. 282, 24131-24145

16. Wang, I. F., Wu, L. S., and Shen, C. K. (2008) Trends Mol. Med. 14, 479-485

17. Lee, E. B., Lee, V. M., and Trojanowski, J. Q. (2012) Nat. Rev. Neurosci. 13, 38-50

18. Amador-Ortiz, C., Lin, W. L., Ahmed, Z., Personett, D., Davies, P., Duara, R., Graff-Radford, N. R., Hutton, M. L., and Dickson, D. W. (2007) Ann. Neurol. 61, 435-445

19. Lee, I. H., and Finkel, T. (2009) J. Biol. Chem. 284, 6322-6328

20. Yi, C., Ma, M., Ran, L., Zheng, J., Tong, J., Zhu, J., Ma, C., Sun, Y., Zhang, S., Feng, W., Zhu, L., Le, Y., Gong, X., Yan, X., Hong, B., Jiang, F. J., Xie, Z., Miao, D., Deng, H., and Yu, L. (2012) Science 336, 474-477

21. Yi, C., and Yu, L. (2012) Autophagy 8, 1-2

22. Kawaguchi, Y., Kovaes, J. J., McLaurin, A., Vance, J. M., Ito, A., and Yao, T. P. (2003) Cell 115, 727-738

23. Lee, J. Y., Koga, H., Kawaguchi, Y., Tang, W., Wong, E., Gao, Y. S., Pandey, U. B., Kaushik, S., Tresse, E., Lu, J., Taylor, J. P., Cuervo, A. M., and Yao, T. P. (2010) EMBO J. 29, 969-980

24. Shintani, T., and Klionsky, D. J. (2004) Science 306, 990-995

25. Knaevelsrud, H., and Simonsen, A. (2010) FEBS Lett. 584, 2635-2645

26. Ravikumar, B., Duden, R., and Rubinsztein, D. C. (2002) Hum. Mol. Genet. 11, 1107-1117

27. Ravikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., and Rubinsztein, D. C. (2004) Nat. Genet. 36, 585-595

28. Nixon, R. A., Wegiel, J., Kumar, A., Yu, W. H., Peterhoff, C., Cataldo, A., and Cuervo, A. M. (2005) J. Neuropathol. Exp. Neurol. 64, 113-122

29. Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., McCluskey, L. F., Miller, B. L., Masliah, E., Mackenzie, I. R., Feldman, H., Feiden, W., Kretzschmar, H. A., Trojanowski, J. Q., and Lee, V. M. (2006) Science 314, 130-133

30. Zhang, Y. J., Xu, Y. F., Dickey, C. A., Buratti, E., Baralle, F., Bailey, R., Pickering-Brown, S., Dickson, D., and Petrucelli, L. (2007) J. Neurosci. 27, 10530-10534

31. Rohn, T. T. (2008) Brain Res. 1228, 189-198
Acknowledgements—We thank Drs Tso-Pang Yao for HDAC6 and Mitsuhiro Okamoto for SIK2 and GST-Syntide plasmids. We are indebted to Dr. Yeu-Kuang Hwu of Academia Sinica & National Synchrotron Radiation Research Center for kindly providing a Jeol 2100F EM, to the Institute of Molecular Biology, Academia Sinica, for the FEI Tecnai G² EM service, and to Hsiao-Hsuian Shen, Shu-Ping Tsai, Wen-Li Peng, Sue-Ping Lee and Yi-Yun Chen for EM technical assistance. We appreciate Yi-Li Liu and I-Ching Huang for their technical expertise on DNA sequencing, supported in part by the Department of Medical Research in NTUH (National Taiwan University Hospital).

FOOTNOTES

This research was funded by grants from National Science Council (NSC96-2321-B-002-008 and NSC100-2320-B-002-008 to S.-C.L.; NSC99-2632-B-182-011-MY3 and NSC101-2320-B-182-036-MY3 and NSC101-2321-B-182-009 to B.C-M.T.) and supported by Academia Sinica (M.-D.T.) and by Institute of Biological Chemistry, Academia Sinica (S.-C.L).

FIGURE LEGENDS

FIGURE 1. SIK2 is acetylated on Lys53 by p300/CBP. (A) FLAG-SIK2 was over-expressed and purified from HEK293T, and subjected to mass spectrometry-based analysis for post-translational modifications (see EXPERIMENTAL PROCEDURES). MS/MS spectra of signal m/z 815.0 that correspond to a trypsinized SIK2 fragment containing Lys53 acetylation. (B) HEK293T cells were transiently transfected with the indicated expression constructs. Recombinant SIK2 was immunoprecipitated and subsequently probed using antibodies against acetylated-lysine or FLAG. Expression of HATs was monitored by anti-HA antibody. (C) Wild-type (WT) or K53R mutant of SIK2 was over-expressed in HEK293T cells, along with HA-p300. Immunoprecipitated recombinant SIK2 as well as lysate input were probed with the indicated antibodies.

FIGURE 2. The ATP-binding ability and kinase activity of SIK2 are both impaired by Lys53-acetylation. (A) HEK293T cells were transfected with the indicated wild-type and mutant SIK2 expression constructs. The recombinant proteins were immunoprecipitated for [γ-35S]ATP binding assay. Quantitative results of the relative ATP binding are presented in the right panel, with the intensity of [γ-35S]ATP being normalized to the corresponding protein level. Bar graph shows mean ± SD of two experimental replicates. (B) Wild-type (WT) or mutant (KD, K53R, and K53Q) SIK2 overexpressing HEK293T cells were harvested and the level of phosphorylated SIK2/Thr175 was analyzed by western blot with Thr175 phospho-specific antibody. (C) HEK293T cells were transiently transfected with the indicated constructs.
The recombinant SIK2 proteins were immunoprecipitated and subjected to *in vitro* kinase reaction with GST-Syntide-2 as the substrate. Vec, vector control; Q, the K53Q mutant; R, the K53R mutant.

**FIGURE 3.** Acetylation-dependent inhibition of SIK2 is reversed by HDAC6-mediated deacetylation. (A) The synthetic SIK2 peptide containing a Lys53 acetylation (KIIDacKSQLDAC) was incubated with recombinant HDAC proteins (HDAC1, 2, 3, 4, 5, 6, and 8). Following the reaction, the mixtures were subjected to mass spectrometric analysis to monitor any changes in the level of peptide acetylation. Extracted ion chromatography of acetylated peptides (left panel) and non-acetylated peptides (right) is shown, illustrating a removal of the acetyl group in the HDAC6-containing reaction. (B) HEK293T cells were transiently transfected with FLAG-SIK2-WT, p300 or HDAC6 in various combinations, as indicated (WT, wild-type; CD, catalytically deficient). Recombinant FLAG-SIK2 was immunoprecipitated and the acetylation level of SIK2 was probed with antibody against acetylated lysine. (C) Acetylated SIK2 protein was immunoprecipitated from the lysates of HEK293T cells ectopically expressing FLAG-SIK2 and HA-p300. The immunoprecipitated SIK2 proteins were then incubated with the indicated deacetylases, and in the absence or presence of the deacetylase inhibitors. Immunoblotting analysis was performed as above. (D) HEK293T cells were transfected with plasmids encoding FLAG-SIK2, FLAG-CBP, and FLAG-HDAC6 in the indicated combinations. Phosphorylation level of SIK2-Thr175 as well as the expression of the recombinant proteins were probed with the denoted antibodies.

**FIGURE 4.** Sequestration of acetylated-SIK2 to autophagosomes. (A) HEK293T cells overexpressing the WT, KD, K53Q, or K53R variant of GFP-SIK2 were analyzed by immunofluorescence staining. Endogenous LC3 (red) was detected by anti-LC3B antibody. The rightmost panel showed GFP-SIK2-WT cells with MG132 (5 μM) treatment for 16 hrs. Scale bar, 10 μm. (B) HEK293T cells were co-transfected with HA-CBP- (or the vector control) and GFP-SIK2-encoding plasmids, followed by immunofluorescence staining of the overexpressed HA-CBP (red) using anti-HA antibody. Scale bar, 10 μm. (C-E) HEK293T cells were treated with or without MG132 (5 μM) for 16 hrs. They were then subjected to immunofluorescence staining (C), separated into soluble (s) and insoluble (p) fractions for protein expression analysis (D), or extracted for anti-SIK2 immunoprecipitation (E). The scale bar in (C) is equivalent to 10 μm. Western blots in (D) & (E) were done using the indicated antibodies. Relative levels of SIK2 acetylation were determined by normalizing the levels of acetylated-SIK2 signals to those of total SIK2 protein in the respective samples, with control sample being represented as 1.

**FIGURE 5.** SIK2 is essential for autophagosome processing. (A) HEK293T cells co-expressed mCherry-GFP-LC3 with siRNA targeting SIK1 or SIK2. After treatment with or without 0.2 μM bafilomycin A1 (BFA) for 16 hrs, cells were fixed and analyzed by immunofluorescence and confocal
microscopy (scale bar, 10 µm). (B) Electron microscopy images of SIK2 knockdown cells. HEK293T cells expressing control (shLuc) or SIK2-targeting (shSIK2) shRNA were subjected to transmission electron microscopy analysis. Control cells were also treated with (shLuc + BFA) or without (shLuc) 0.2 µM bafilomycin A₁ for 16 hrs. Bottom figures represent enlarged images of the boxed regions in the top figures. Arrow, autophagosome; M, mitochondria; N, nucleus. Scale bar, 1 µm.

FIGURE 6. SIK2 co-localizes with the TDP-43Δ inclusion bodies. (A) HEK293T cells ectopically expressing GFP-hTDP43Δ were fixed and immunostained with anti-ubiquitin (upper) or anti-SIK2 (lower) antibodies. Scale bar, 10 µm. (B) Cells were co-transfected with GFP-hTDP43Δ- and FLAG-SIK2-encoding plasmids, followed by immunofluorescence staining using anti-FLAG antibody. Single-section images of confocal microscopy were acquired and shown (Scale bar, 10 µm).

FIGURE 7. SIK2 is required for the processing/removal of TDP-43Δ inclusion bodies. (A) & (B) HEK293T cells were transfected with plasmids expressing luciferase- or SIK2-targeting shRNAs (A), or the WT, KD, K53Q, or K53R variant of SIK2 (B). GFP-hTDP43Δ was also co-expressed. Cell extracts were separated into soluble (S) and insoluble (P) fractions. Insoluble fractions were analyzed by slot blot assay using anti-GFP antibody (top left panel). Soluble and insoluble fractions (middle) and whole-cell extracts (top right panel) were probed with the indicated antibodies to show the expression levels of various proteins. Bar graph in the bottom panel shows the quantification of GFP-hTDP43Δ intensity on the slot-blot. Means and standard deviations were calculated from 3 independent experiments. *p < 0.05. (C) HEK293T cells were transiently transfected plasmids for the co-expression of: GFP-hTDP43Δ with FLAG-SIK2 WT or KD (left panel), or GFP-hTDP43Δ with control shRNA or SIK2-targeting shRNA (right). Forty-eight hrs after transfection, cells were fixed and analyzed for the proportion of aggresome-containing cells. Quantitative data are means ± SD of two independent experiments (*p < 0.05).

FIGURE 8. SIK2 kinase activity, controlled by an acetylation-based regulatory switch, contributes to the progression of autophagy. Upon proteasome inhibition, SIK2 is inhibited by p300/CBP-mediated Lys53 acetylation and sequestered to autophagosomes. Deacetylation of SIK2 by HDAC6 in autophagosomes likely reactivates SIK2 and promotes autophagosome processing. (See text for discussion.)
FIGURE 1

A

B

C

IP: FLAG

|        | IP: FLAG |         |         |         |         | IB:       |
|--------|----------|---------|---------|---------|---------|-----------|
| HA-p300| -        | -       | +       | -       | -       | Ac-SIK2   |
| HA-CBP | -        | -       | -       | +       | -       | SIK2      |
| HA-Tip60| -      | -       | -       | -       | +       |           |
| FLAG-SIK2| -     | +       | +       | +       | +       |           |

Total cell lysate

|        | 1   | 2   | 3   | 4   | 5   |
|--------|-----|-----|-----|-----|-----|
| p300CBP|      |     |     |     |     |
| Tip60  |      |     |     |     |     |
| α-tubulin|    |     |     |     |     |

HA-p300

FLAG-SIK2

WT

K53R

WT

K53R

IB:

Ac-SIK2

SIK2

Total cell lysate

p300

SIK2

α-tubulin
FIGURE 2

A

| SIK2 | SIK2 |
|------|------|
| WT   | KD   |
| K53R | KD   |
| 35S  |

1. Coomassie
2. 35S

B

FLAG-SIK2  WT  K53R  K53Q  KD  IB:

1. T175-P SIK2
2. SIK2
3. β-actin

C

FLAG-SIK2  Vec  KD  WT  Q  R  Vec  KD  WT  Q  R

1. Coomassie
2. 35P

SIK2

Syntide-2
FIGURE 4

A

SIK2-WT  SIK2-KD  SIK2-K53Q  SIK2-K53R  SIK2-WT +MG132

SIK2

LC3

Merge

B

SIK2  HA  Merge

GFP-SIK2 +Vector

GFP-SIK2 +HA-CBP

GFP-SIK2-K53R +HA-CBP

C

SIK2  LC3  Merge

control

MG132

D

MG132

-  +  -  +  -  +

IB:

Ub

SIK2

α-tubulin

γ-tubulin

E

IP: SIK2

MG132

-  +  -  +

IB:

Ac-SIK2

SIK2

Input

SIK2

α-tubulin
FIGURE 6

A

B
FIGURE 8
Reversible Acetylation Regulates Salt-Inducible Kinase (SIK2) and Its Function in Autophagy

Fu-Chia Yang, Bertrand Chin-Ming Tan, Wei-Hao Chen, Ya-Huei Lin, Jing-Yi Huang, Hsin-Yun Chang, Hui-Yu Sun, Pang-Hung Hsu, Gunn-Guang Liou, James Shen, Ching-Jin Chang, Chau-Chung Han, Ming-Daw Tsai and Sheng-Chung Lee

J. Biol. Chem. published online January 15, 2013

Access the most updated version of this article at doi: 10.1074/jbc.M112.431239

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

Supplemental material:
http://www.jbc.org/content/suppl/2013/01/15/M112.431239.DC1